Douglas F Kling

US Patent:

20100010026, Jan 14, 2010

Filed:

Sep 17, 2009

Appl. No.:

12/561558

Inventors:

Roelof M.L. RONGEN - Califon NJ, US
Robert A. SHALWITZ - Bexley OH, US
Douglas KLING - Parsippany NJ, US

International Classification:

A61K 31/505
A61K 31/47
A61K 31/404
A61K 31/40
A61K 31/366
A61K 31/202

US Classification:

514275, 514311, 514419, 514423, 514460, 514560

Abstract:

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

US Patent:

20110251275, Oct 13, 2011

Filed:

Jan 10, 2011

Appl. No.:

12/987484

Inventors:

Roelof M.L. Rongen - Califon NJ, US
Douglas Kling - Parsippany NJ, US
Robert A. Shalwitz - Bexley OH, US

International Classification:

A61K 31/202
A61P 9/00
A61P 9/10
A61K 31/366
A61P 3/06

US Classification:

514460, 514560

Abstract:

Methods are provided for utilizing omega-3 fatty acids, or a combination of a dyslipidemic agent and omega-3 fatty acids, for the reduction of lipoprotein-associated phospholipase A(Lp-PLA) levels. The methods are especially useful in the treatment of patients with primary hypercholesterolemia or hypertriglyceridemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of major adverse cardiovascular events (MACE), major coronary events (MCE), particularly myocardial infarction (MI), revascularizations and ischemic stroke.

US Patent:

20080085911, Apr 10, 2008

Filed:

Sep 7, 2007

Appl. No.:

11/851867

Inventors:

Roelof M.L. Rongen - Califon NJ, US
Robert A. Shalwitz - Bexley OH, US
Douglas Kling - Parsippany NJ, US
Ralph T. Doyle - Milford NJ, US

Assignee:

Reliant Pharmaceuticals, Inc. - Liberty Corner NJ

International Classification:

A61K 31/20
A61K 31/225
A61K 31/35
A61K 31/40
A61K 31/405
A61K 31/47
A61K 31/505
A61P 3/00

US Classification:

514275, 514311, 514415, 514423, 514460, 514548, 514560

Abstract:

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.